Treatment patterns and outcomes in metastatic synovial sarcoma: a real-world study in the US oncology network
Abstract
Aim: To examine and understand patient characteristics, treatment patterns and outcomes for patients with metastatic synovial sarcoma (mSS) treated in a US community setting. Materials & methods: Retrospective observational study in adults with mSS in The US Oncology Network (diagnosed January 2012–December 2018). Results: Of 202 patients diagnosed with SS, 71 had mSS. Of 39 patients with mSS who received first-line (1L) systemic treatment, 25 and 16 continued to second-line and 3L+ treatment, respectively. With each subsequent treatment line, time to treatment discontinuation (1L–3L: 3.9–2.7 months) and time to next treatment (1L–3L: 9.3–4.6 months) decreased. At 1L, median overall survival was 24.5 months. Conclusion: This study highlights the ongoing need for effective therapies for mSS.
